Redeye leaves its Fundamental Value (Base Case) unchanged at SEK34 as higher 2026–27 EBITDA-CAPEX estimates on the Q3 beat are offset by a higher risk-free rate. Medsum and Infosolutions impress, while Germany lags. We still see Carasent as one of our most attractive SaaS cases.
LÄS MER
